GRAIL INC (GRAL) Stock Price, Forecast & Analysis
NASDAQ:GRAL • US3847471014
GRAL Key Statistics, Chart & Performance
The current stock price of GRAL is 100.4 USD. In the past month the price decreased by -1.54%. In the past year, price increased by 82.48%.
GRAL Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to GRAL. When comparing the yearly performance of all stocks, GRAL is one of the better performing stocks in the market, outperforming 92.99% of all stocks.
GRAL Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to GRAL. GRAL has a great financial health rating, but its profitability evaluates not so good.
GRAL Financial Highlights
Over the last trailing twelve months GRAL reported a non-GAAP Earnings per Share(EPS) of -11.64. The EPS increased by 90.18% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -15.62% | ||
| ROE | -18.14% | ||
| Debt/Equity | 0 |
GRAL Forecast & Estimates
10 analysts have analysed GRAL and the average price target is 107.1 USD. This implies a price increase of 6.67% is expected in the next year compared to the current price of 100.4.
For the next year, analysts expect an EPS growth of 82.19% and a revenue growth 18.96% for GRAL
GRAL Ownership
GRAL Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.21 | 390.397B | ||
| AMGN | AMGEN INC | 16.27 | 197.396B | ||
| GILD | GILEAD SCIENCES INC | 17.47 | 193.298B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.62 | 117.026B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.77 | 81.87B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 48.11 | 42.576B | ||
| INSM | INSMED INC | N/A | 31.656B | ||
| NTRA | NATERA INC | N/A | 29.322B | ||
| BIIB | BIOGEN INC | 12.57 | 28.06B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.15 | 20.49B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About GRAL
Company Profile
GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. The company is headquartered in Menlo Park, California and currently employs 1,000 full-time employees. The company went IPO on 2024-06-12. The firm is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer.
Company Info
GRAIL INC
1525 O'brien Drive
Menlo Park CALIFORNIA US
Employees: 1000
Phone: 18336942553
GRAIL INC / GRAL FAQ
Can you describe the business of GRAIL INC?
GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. The company is headquartered in Menlo Park, California and currently employs 1,000 full-time employees. The company went IPO on 2024-06-12. The firm is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer.
Can you provide the latest stock price for GRAIL INC?
The current stock price of GRAL is 100.4 USD. The price decreased by -3.16% in the last trading session.
Does GRAIL INC pay dividends?
GRAL does not pay a dividend.
What is the ChartMill technical and fundamental rating of GRAL stock?
GRAL has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
On which exchange is GRAL stock listed?
GRAL stock is listed on the Nasdaq exchange.
What is GRAIL INC worth?
GRAIL INC (GRAL) has a market capitalization of 3.91B USD. This makes GRAL a Mid Cap stock.
Can you provide the ownership details for GRAL stock?
You can find the ownership structure of GRAIL INC (GRAL) on the Ownership tab.